Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease

Cited by (1,001)

Items 201–300 of 1,001

1. Gene editing and its applications in biomedicine
   Guanglei Li, Xiangyang Li, Songkuan Zhuang, Liren Wang, Yifan Zhu, Yangcan Chen, Wen Ce Sun, Zeguang Wu, Zhuo Long Zhou, Jia Chen et al. · 2022 · Science China Life Sciences
2. Lipid-lowering in diabetes: An update
   Alan Chait, Robert H. Eckel, Michal Vrablı́k, Alberto Zambon · 2023 · Atherosclerosis
3. Triglyceride metabolism and angiopoietin-like proteins in lipoprotein lipase regulation
   Jing Li, Liang Li, Dongming Guo, Suyun Li, YuXin Zeng, Chu‐Hao Liu, Ru Fu, Mengqian Huang, Wei Xie · 2020 · Clinica Chimica Acta
4. Quinoa Seed Lowers Serum Triglycerides in Overweight and Obese Subjects: A Dose-Response Randomized Controlled Clinical Trial
   Diana Navarro-Perez, Jessica Radcliffe, Audrey C. Tierney, Markandeya Jois · 2017 · Current Developments in Nutrition
5. D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile
   Sophie Valleix, Guglielmo Verona, Noémie Jourde‐Chiche, Brigitte Nédelec, Palma Patrizia Mangione, Frank Bridoux, Alain Mangé, Ahmet Doǧan, Jean‐Michel Goujon, Marie Lhomme et al. · 2016 · Nature Communications
6. Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII
   Haibo Li, Yingchun Han, Rong Qi, Yuhui Wang, Xiao­hong Zhang, Maomao Yu, Yin Tang, Mengyu Wang, Ya-Nan Shu, Wei Y. Huang et al. · 2015 · Cardiovascular Research
7. Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases
   Werner J. Geldenhuys, Lin Li, Altaf S. Darvesh, Prabodh Sadana · 2016 · Drug Discovery Today
8. Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids
   Weinberg, Richard L., Brook, Robert D., Rubenfire, Melvyn, Eagle, Kim A. · 2021 · Journal of the American College of Cardiology
9. New Therapies for Lowering Triglyceride-Rich Lipoproteins
   Robert S. Rosenson, Aleesha Shaik, Wen‐Liang Song · 2021 · Journal of the American College of Cardiology
10. Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia
    Maki, Kevin C., Guyton, John R., Orringer, Carl E., Hamilton-Craig, Ian, Alexander, Dominik D., Davidson, Michael H. · 2016 · Journal of Clinical Lipidology
11. New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
    Alberto J. Lorenzatti, Peter Paul Toth · 2020 · European Cardiology Review
12. Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance
    Chris J. Packard, Angela Pirillo, Sotirios Tsimikas, Brian A. Ference, Alberico Luigi Catapano · 2023 · Cardiovascular Research
13. Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profile testing: a 2019 Expert Panel Statement, Main Text
    Kolovou, Genovefa D., Watts, Gerald F., Mikhailidis, Dimitri P., Pérez-Martínez, Pablo, Mora, Samia, Bilianou, Helen, Panotopoulos, George, Katsiki, Niki, Ooi, Teik C., Lopez-Miranda, José et al. · 2019 · Current Vascular Pharmacology
14. Triglycerides and residual risk
    Antonio J. Vallejo‐Vaz, Pablo Corral, Laura Ester Schreier, Kausik Kumar Ray · 2020 · Current Opinion in Endocrinology Diabetes and Obesity
15. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets
    Ioannis Akoumianakis, Evangelia Zvintzou, Kyriakos E. Kypreos, Theodosios D. Filippatos · 2021 · Current Atherosclerosis Reports
16. RNA-targeted therapeutics for lipid disorders
    Sotirios Tsimikas · 2018 · Current Opinion in Lipidology
17. Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes
    Anastasia‐Stefania Alexopoulos, Ali Qamar, Kathryn Hutchins, Matthew J. Crowley, Bryan C. Batch, John R. Guyton · 2019 · Current Diabetes Reports
18. Association of Genetically Predicted Lipid Levels With the Extent of Coronary Atherosclerosis in Icelandic Adults
    Eyþór Björnsson, Guðmar Þorleifsson, Anna Helgadóttir, Þórarinn Guðnason, Tómas Guðbjartsson, Karl K Andersen, Sólveig Grétarsdóttir, Ísleifur Ólafsson, Vinicius Tragante, Ólafur Ólafsson et al. · 2019 · JAMA Cardiology
19. Obesity and Cardiovascular Disease: The Emerging Role of Inflammation
    Rana Tarek Mohamed Khafagy, Satya Dash · 2021 · Frontiers in Cardiovascular Medicine
20. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance
    Ramms, Bastian, Patel, Sohan, Nora, Chelsea, Pessentheiner, Ariane R., Chang, Max W., Green, Courtney R., Golden, Gregory J., Secrest, Patrick, Krauss, Ronald M., Metallo, Christian M. et al. · 2019 · Journal of Lipid Research
21. Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias
    Clarice Gareri, Alberto Polimeni, Salvatore A. Giordano, Laura Tammè, Antonio Curcio, Ciro Indolfi · 2022 · Journal of Clinical Medicine
22. Updates in Drug Treatment of Severe Hypertriglyceridemia
    Gouni-Berthold, Ioanna, Schwarz, Jonas, Berthold, Heiner K. · 2023 · Current Atherosclerosis Reports
23. Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease
    Wayne C. Zheng, William Chan, Anthony Michael Dart, James A. Shaw · 2023 · European Heart Journal - Cardiovascular Pharmacotherapy
24. Mendelian randomization to assess causal effects of blood lipids on coronary heart disease
    Stephen Burgess, Eric L. Harshfield · 2016 · Current Opinion in Endocrinology Diabetes and Obesity
25. ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity
    Mengdie Luo, Aiying Liu, Shuai Wang, Tianle Wang, Die Hu, Sha Wu, Daoquan Peng · 2017 · Scientific Reports
26. Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients
    Peter Paul Toth, Sephy Philip, MICHAEL L. HULL, Craig B. Granowitz · 2019 · Mayo Clinic Proceedings
27. Therapeutic RNA-silencing oligonucleotides in metabolic diseases
    Goga, Algera, Stoffel, Markus · 2022 · Nature Reviews Drug Discovery
28. New Era of Lipid-Lowering Drugs
    Philip J. Barter, Kerry‐Anne Rye · 2016 · Pharmacological Reviews
29. A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects
    Baohai Shao, Ian H. de Boer, Chongren Tang, Philip S. Mayer, Leila R. Zelnick, Maryam Afkarian, Jay W. Heinecke, Jonathan Himmelfarb · 2015 · Journal of Proteome Research
30. Knowns and unknowns for psychophysiological endophenotypes: integration and response to commentaries
    Iacono, William G., Vaidyanathan, Uma, Vrieze, Scott I., Malone, Stephen M. · 2014 · Psychophysiology
31. Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia
    Adiels, Martin, Taskinen, Marja‐Riitta, Björnson, Elias, Andersson, Linda, Matikainen, Niina, Söderlund, Sanni, Kahri, Juhani, Hakkarainen, Antti, Lundbom, Nina, Sihlbom, Carina et al. · 2019 · Diabetes, Obesity and Metabolism
32. Genetic Variants Associated With Increased Plasma Levels of Triglycerides, via Effects on the Lipoprotein Lipase Pathway, Increase Risk of Acute Pancreatitis
    Signe E J Hansen, Christian Medom Madsen, Anette Varbo, Anne Tybjærg‐Hansen, Børge Grønne Nordestgaard · 2020 · Clinical Gastroenterology and Hepatology
33. Rare coding variants in 35 genes associate with circulating lipid levels—A multi-ancestry analysis of 170,000 exomes
    George Hindy, Peter Dornbos, Mark D. Chaffin, Dajiang J. Liu, Minxian Wang, Margaret Sunitha Selvaraj, David Zhang, Joseph Park, Carlos Alberto Aguilar-Salinas, Lucinda Fulton et al. · 2021 · The American Journal of Human Genetics
34. Hypertriglyceridemia and Cardiovascular Diseases: Revisited
    Seung Hwan Han, Stephen James Nicholls, Ichiro Sakuma, Dong Hui Zhao, Kwang Kon Koh · 2016 · Korean Circulation Journal
35. Loss-of-function variants influence the human serum metabolome
    Bing Yu, Alexander H. Li, Ginger Metcalf, Donna Marie Muzny, Alanna C. Morrison, Simon J. White, Thomas H. Mosley, Richard A. Gibbs, Eric Boerwinkle · 2016 · Science Advances
36. Triglycerides and ASCVD risk reduction: recent insights and future directions
    Hussain, Aliza, Ballantyne, Christie M., Saeed, Anum, Virani, Salim S · 2020 · Current Atherosclerosis Reports
37. From Loci to Biology
    Sylvia Nürnberg, Hanrui Zhang, Nicholas J. Hand, Robert C. Bauer, Danish Saleheen, Muredach P. Reilly, Daniel James Rader · 2016 · Circulation Research
38. Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome
    Alejandro Gugliucci, Robert H. Lustig, Russell J. Caccavello, Ayca Erkin‐Cakmak, Susan Moyher Noworolski, Viva Tai, Michael Wen, Kathleen M. Mulligan, Jean‐Marc Schwarz · 2016 · Atherosclerosis
39. The RNA-binding protein vigilin regulates VLDL secretion through modulation of Apob mRNA translation
    Mobin, Mehrpouya B., Gerstberger, Stefanie, Teupser, Daniel, Campana, Benedetta, Charisse, Klaus, Heim, Markus H., Manoharan, Muthiah, Tuschl, Thomas, Stoffel, Markus · 2016 · Nature Communications
40. Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease
    Biterova, Ekaterina, Esmaeeli, Mariam, Alanen, Heli I., Saaranen, Mirva, Ruddock, Lloyd W. · 2018 · Scientific Reports
41. Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real‐world evidence
    Peter Paul Toth, Sergio Fazio, Nathan D. Wong, MICHAEL L. HULL, Gregory A. Nichols · 2019 · Diabetes Obesity and Metabolism
42. ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen
    Rocha, Natalia A., East, Cara, Zhang, Jun, McCullough, Peter A. · 2017 · Current Atherosclerosis Reports
43. Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease
    Bratati Kahali, Brian D. Halligan, Elizabeth K. Speliotes · 2015 · Seminars in Liver Disease
44. Target Populations for Novel Triglyceride-Lowering Therapies
    Nordestgaard, Ask T., Tybjærg-Hansen, Anne, Mansbach, Hank, Kersten, Sander, Nordestgaard, Børge G., Rosenson, Robert S. · 2025 · Journal of the American College of Cardiology
45. Analysis of loss-of-function variants and 20 risk factor phenotypes in 8,554 individuals identifies loci influencing chronic disease
    Alexander H. Li, Alanna C. Morrison, Christie Kovar, L. Adrienne Cupples, Jennifer A. Brody, Linda M. Polfus, Bing Yu, Ginger Metcalf, Donna Marie Muzny, Narayanan Veeraraghavan et al. · 2015 · Nature Genetics
46. Personalized medicine for cardiovascular diseases
    Hayato Tada, Noboru Fujino, Akihiro Nomura, Chiaki Nakanishi, Kenshi Hayashi, Masayuki Takamura, Masa‐aki Kawashiri · 2020 · Journal of Human Genetics
47. Human genetics of HDL: Insight into particle metabolism and function
    Liam R. Brunham, Michael R. Hayden · 2015 · Progress in Lipid Research
48. Vascular proteomics in metabolic and cardiovascular diseases
    Magnus Lynch, Javier Barallobre‐Barreiro, Marjan Jahangiri, Manuel Mayr · 2016 · Journal of Internal Medicine
49. Triglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids
    Yehuda Handelsman, Michael David Shapiro · 2016 · Endocrine Practice
50. Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL
    Mikael Larsson, Christopher M. Allan, Rachel S. Jung, Patrick J. Heizer, Anne P. Beigneux, Stephen G. Young, Loren G. Fong · 2017 · Journal of Lipid Research
51. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial
    Dunbar, Richard L., Nicholls, Stephen J., Maki, Kevin C., Roth, Eli M., Orloff, David G., Curcio, Danielle, Johnson, Judith, Kling, Douglas, Davidson, Michael H. · 2015 · Lipids in Health and Disease
52. Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels
    Wensheng Lu, Yi‐Chiao Cheng, Kong Y. Chen, H. Wang, Glenn S. Gerhard, Christopher D. Still, Xin Chu, Runxu Yang, A. Parihar, Jeffery R. O’Connell et al. · 2015 · Human Molecular Genetics
53. The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism
    Mengdie Luo, Daoquan Peng · 2016 · Lipids in Health and Disease
54. Kidney function is associated with an altered protein composition of high-density lipoprotein
    Katya B. Rubinow, Clark M. Henderson, Cassianne Robinson‐Cohen, Jonathan Himmelfarb, Ian H. de Boer, Tomáš Vaisar, Bryan R. Kestenbaum, Andrew N. Hoofnagle · 2017 · Kidney International
55. The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis
    Philip L.S.M. Gordts, Jeffrey D. Esko · 2018 · Matrix Biology
56. Emerging Concepts in Precision Medicine and Cardiovascular Diseases in Racial and Ethnic Minority Populations
    George A. Mensah, Cashell E. Jaquish, Pothur R. Srinivas, George Papanicolaou, Gina S. Wei, Nicole Redmond, Megan Clarke Roberts, Cheryl R. Nelson, Larissa M. Avilés-Santa, Mona A. Puggal et al. · 2019 · Circulation Research
57. The FANC/BRCA Pathway Releases Replication Blockades by Eliminating DNA Interstrand Cross-Links
    Xavier Renaudin, Filippo Rosselli · 2020 · Genes
58. Advances in Genomics for Drug Development
    Roberto Spreafico, Leah B. Soriaga, Johannes Grosse, Herbert W. Virgin, Amalio Telenti · 2020 · Genes
59. ApoCIII: A multifaceted protein in cardiometabolic disease
    Laura D’Erasmo, Alessia Di Costanzo, Antonio Gallo, Éric Bruckert, Marcello Arca · 2020 · Metabolism
60. Update on the laboratory investigation of dyslipidemias
    Ramasamy, I. · 2018 · Clinica Chimica Acta
61. Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective
    Parhofer, Klaus G. · 2015 · Atherosclerosis Supplements
62. Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects
    Genmao Cao, Xuezhen Xuan, Ruijing Zhang, Jie Hong Hu, Honglin Dong · 2021 · Frontiers in Cardiovascular Medicine
63. A Novel Apolipoprotein C-II Mimetic Peptide That Activates Lipoprotein Lipase and Decreases Serum Triglycerides in Apolipoprotein E–Knockout Mice
    Marcelo J. Amar, Toshihiro Sakurai, Akiko Sakurai-Ikuta, Denis O. Sviridov, Lita A. Freeman, Lusana Ahsan, Alan Thomas Remaley · 2014 · Journal of Pharmacology and Experimental Therapeutics
64. The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides
    Hussein N. Yassine, Olgica Trenchevska, Ambika Ramrakhiani, Aarushi Parekh, Juraj Koška, Ryan W. Walker, Dean D. Billheimer, Peter D. Reaven, Frances T. Yen, Randall W. Nelson et al. · 2015 · PLoS ONE
65. Nuclear magnetic resonance lipoprotein abnormalities in newly-diagnosed type 2 diabetes and their association with preclinical carotid atherosclerosis
    Antonio Jesús Amor, Marta Catalán, Antonio Pérez, Zoe Herreras, Montserrat Pinyol, Aleix Sala‐Vila, Montserrat Cofán, Rosa Gilabert, Emilio Ros, Emilio Ortega · 2016 · Atherosclerosis
66. Pathway and network-based strategies to translate genetic discoveries into effective therapies
    Casey S. Greene, Benjamin F. Voight · 2016 · Human Molecular Genetics
67. Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies
    Hayato Tada, Atsushi Nohara, Masa‐aki Kawashiri · 2018 · Nutrients
68. The effects of oleoylethanolamide, an endogenous PPAR‐α agonist, on risk factors for NAFLD: A systematic review
    Helda Tutunchi, Alireza Ostadrahimi, Maryam Saghafi‐Asl, Vahid Maleki · 2019 · Obesity Reviews
69. Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanistic Studies in Animal Models
    Debapriya Basu, Karin Bornfeldt · 2020 · Frontiers in Endocrinology
70. Human genetics and its impact on cardiovascular disease
    Hayato Tada, Noboru Fujino, Kenshi Hayashi, Masa‐aki Kawashiri, Masayuki Takamura · 2021 · Journal of Cardiology
71. Hypertriglyceridemia
    Alan Chait · 2022 · Endocrinology and Metabolism Clinics of North America
72. Exome Sequencing Analysis in Severe, Early-Onset Chronic Obstructive Pulmonary Disease
    Dandi Qiao, Christoph Lange, Terri H. Beaty, James D. Crapo, Kathleen C. Barnes, Michael J. Bamshad, Craig P. Hersh, Jarrett D. Morrow, Víctor Pinto-Plata, Nathaniel T. Marchetti et al. · 2016 · American Journal of Respiratory and Critical Care Medicine
73. A Comparative Overview of Prescription Omega-3 Fatty Acid Products.
    Matthew K. Ito · 2015 · PubMed Central
74. Zebrafish Models for Dyslipidemia and Atherosclerosis Research
    Amnon Schlegel · 2016 · Frontiers in Endocrinology
75. The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases
    Nicholas Chew, Bryan Chong, Cheng Han Ng, Gwyneth Kong, Yip Han Chin, Wang Xiao, Chang Jie Mick Lee, Yock Young Dan, Mark Dhinesh Muthiah, Roger Foo · 2022 · Frontiers in Genetics
76. Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future
    Alan Chait, Robert H. Eckel · 2016 · The Journal of Clinical Endocrinology & Metabolism
77. Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials
    Amirhossein Sahebkar, Luis E. Simental‐Mendía, Dimitri P. Mikhailidis, Matteo Pirro, Maciej Banach, Cesare Riccardo Sirtori, Željko Reiner · 2018 · Annals of Medicine
78. Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human: A Mendelian randomization study
    Ching‐Lung Cheung, K. C. B. Tan, Philip Chun-Ming Au, Gloria Hoi‐Yee Li, Bernard M.Y. Cheung · 2019 · EBioMedicine
79. Rare protein-altering variants in ANGPTL7 lower intraocular pressure and protect against glaucoma
    Yosuke Tanigawa, Michael Wainberg, Juha M Karjalainen, Tuomo Kiiskinen, Guhan Ram Venkataraman, Susanna M. Lemmelä, Joni A. Turunen, Robert Graham, Aki Samuli Havulinna, Markus Perola et al. · 2020 · PLoS Genetics
80. Apolipoprotein E and Atherosclerosis
    Adrian David Marais · 2021 · Current Atherosclerosis Reports
81. Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms
    Trenchevska, Olgica, Schaab, Matthew R., Nelson, Randall W., Nedelkov, Dobrin · 2015 · Methods
82. Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets
    Chen, Jingfei, Fang, Zhenfei, Luo, Qin, Wang, Xiao, Warda, Mohamad, Das, Avash, Oldoni, Federico, Luo, Fei · 2024 · Lipids in Health and Disease
83. HDL re-examined
    G. Kees Hovingh, Daniel James Rader, Robert Alexander Hegele · 2015 · Current Opinion in Lipidology
84. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies
    Ballantyne, Christie M., Bays, Harold E., Braeckman, Rene A., Philip, Sephy, Stirtan, William G., Doyle, Ralph T., Soni, Paresh N., Juliano, Rebecca A. · 2016 · Journal of Clinical Lipidology
85. Association of APOC3 Loss-of-Function Mutations With Plasma Lipids and Subclinical Atherosclerosis
    Pradeep Natarajan, Puja Kohli, Usman Baber, Khanh-Dung Hoang Nguyen, Samantha Sartori, Dermot F. Reilly, Roxana Mehran, Pieter Muntendam, Valentı́n Fuster, Daniel James Rader et al. · 2015 · Journal of the American College of Cardiology
86. Neuroendocrinological and Epigenetic Mechanisms Subserving Autonomic Imbalance and HPA Dysfunction in the Metabolic Syndrome
    Erwin Lemche, Олег Чабан, Alexandra V. Lemche · 2016 · Frontiers in Neuroscience
87. Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects
    Björnson, E., Packard, C.J., Adiels, M., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Lundbom, J. et al. · 2020 · Journal of Internal Medicine
88. Small Dense Low-Density Lipoprotein Cholesterol: A Residual Risk for Rapid Progression of Non-Culprit Coronary Lesion in Patients with Acute Coronary Syndrome
    Teruo Sekimoto, Shinji Koba, Hiroyoshi Mori, Rikuo Sakai, Taito Arai, Yuya Yokota, Shunya Sato, Hideaki Tanaka, Ryota Masaki, Yosuke Oishi et al. · 2021 · Journal of Atherosclerosis and Thrombosis
89. Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
    Joon Ho Moon, Kyuho Kim, Sung Hee Choi · 2022 · Endocrinology and Metabolism
90. Gene therapy and genome editing for lipoprotein disorders
    Chen Gurevitz, Archna Bajaj, Amit V. Khera, Ron Do, Heribert Schunkert, Kiran Musunuru, Robert S. Rosenson · 2025 · European Heart Journal
91. APOC3, Coronary Disease, and Complexities of Mendelian Randomization
    Jonathan C. Cohen, Stefan Stender, Helen H. Hobbs · 2014 · Cell Metabolism
92. Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches
    Teemu Niiranen, Ramachandran Srini Vasan · 2016 · Expert Review of Cardiovascular Therapy
93. A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids
    Dean G. Karalis · 2016 · Advances in Therapy
94. South Asian medical cohorts reveal strong founder effects and high rates of homozygosity
    Jeffrey D. Wall, J. Fah Sathirapongsasuti, Ravi Kr Gupta, Asif Rasheed, Venkatesan Radha, Saurabh Belsare, Ramesh Menon, Sameer Phalke, Anuradha Mittal, John Z. Fang et al. · 2023 · Nature Communications
95. Apolipoprotein C3: form begets function
    Karin Bornfeldt · 2023 · Journal of Lipid Research
96. Triglyceride and cardiovascular risk: A critical appraisal
    Awadhesh Kumar Singh, Ritu Singh · 2016 · Indian Journal of Endocrinology and Metabolism
97. Rare coding variants pinpoint genes that control human hematological traits
    Abdou Mousas, Georgios Ntritsos, Ming‐Huei Chen, Ci Song, Jennifer E. Huffman, Ioanna Tzoulaki, Paul Elliott, Bruce M. Psaty, Paul Livermore Auer, Andrew D. Johnson et al. · 2017 · PLoS Genetics
98. Vaccination in Atherosclerosis
    Felix Sebastian Nettersheim, Lauren De Vore, Holger Winkels · 2020 · Cells
99. Novel therapeutics in hypertriglyceridemia
    Gryn, Steven E., Hegele, Robert A. · 2015 · Current Opinion in Lipidology
100. Per-Particle Triglyceride-Rich Lipoproteins Imply Higher Myocardial Infarction Risk Than Low-Density Lipoproteins: Copenhagen General Population Study
     Mia Ø Johansen, Signe Vedel‐Krogh, Sune Fallgaard Nielsen, Shoaib Afzal, George Davey Smith, Børge Grønne Nordestgaard · 2021 · Arteriosclerosis Thrombosis and Vascular Biology